Cargando…
Erythrocyte Inosine triphosphatase activity: A potential biomarker for adverse events during combination antiretroviral therapy for HIV
The purine analogues tenofovir and abacavir are precursors of potential substrates for the enzyme Inosine 5’-triphosphate pyrophosphohydrolase (ITPase). Here, we investigated the association of ITPase activity and ITPA genotype with the occurrence of adverse events (AEs) during combination antiretro...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766130/ https://www.ncbi.nlm.nih.gov/pubmed/29329318 http://dx.doi.org/10.1371/journal.pone.0191069 |
_version_ | 1783292319858950144 |
---|---|
author | Peltenburg, N. Chantal Bierau, Jörgen Bakker, Jaap A. Schippers, Jolanda A. Lowe, Selwyn H. Paulussen, Aimée D. C. van den Bosch, Bianca J. C. Leers, Mathie P. G. Hansen, Bettina E. Verbon, Annelies |
author_facet | Peltenburg, N. Chantal Bierau, Jörgen Bakker, Jaap A. Schippers, Jolanda A. Lowe, Selwyn H. Paulussen, Aimée D. C. van den Bosch, Bianca J. C. Leers, Mathie P. G. Hansen, Bettina E. Verbon, Annelies |
author_sort | Peltenburg, N. Chantal |
collection | PubMed |
description | The purine analogues tenofovir and abacavir are precursors of potential substrates for the enzyme Inosine 5’-triphosphate pyrophosphohydrolase (ITPase). Here, we investigated the association of ITPase activity and ITPA genotype with the occurrence of adverse events (AEs) during combination antiretroviral therapy (cART) for human immunodeficiency virus (HIV) infection. In 393 adult HIV-seropositive patients, AEs were defined as events that led to stop of cART regimen. ITPase activity ≥4 mmol IMP/mmol Hb/hour was considered as normal. ITPA genotype was determined by testing two ITPA polymorphisms: c.94C>A (p.Pro32Thr, rs1127354) and c.124+21A>C (rs7270101). Logistic regression analysis determined odds ratios for developing AEs. In tenofovir-containing regimens decreased ITPase activity was associated with less AEs (p = 0.01) and longer regimen duration (p = 0.001). In contrast, in abacavir-containing regimens decreased ITPase activity was associated with more AEs (crude p = 0.02) and increased switching of medication due to AEs (p = 0.03). ITPA genotype wt/wt was significantly associated with an increase in the occurrence of AEs in tenofovir-containing regimens. Decreased ITPase activity seems to be protective against occurrence of AEs in tenofovir-containing cART, while it is associated with an increase in AEs in abacavir-containing regimens. |
format | Online Article Text |
id | pubmed-5766130 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-57661302018-01-23 Erythrocyte Inosine triphosphatase activity: A potential biomarker for adverse events during combination antiretroviral therapy for HIV Peltenburg, N. Chantal Bierau, Jörgen Bakker, Jaap A. Schippers, Jolanda A. Lowe, Selwyn H. Paulussen, Aimée D. C. van den Bosch, Bianca J. C. Leers, Mathie P. G. Hansen, Bettina E. Verbon, Annelies PLoS One Research Article The purine analogues tenofovir and abacavir are precursors of potential substrates for the enzyme Inosine 5’-triphosphate pyrophosphohydrolase (ITPase). Here, we investigated the association of ITPase activity and ITPA genotype with the occurrence of adverse events (AEs) during combination antiretroviral therapy (cART) for human immunodeficiency virus (HIV) infection. In 393 adult HIV-seropositive patients, AEs were defined as events that led to stop of cART regimen. ITPase activity ≥4 mmol IMP/mmol Hb/hour was considered as normal. ITPA genotype was determined by testing two ITPA polymorphisms: c.94C>A (p.Pro32Thr, rs1127354) and c.124+21A>C (rs7270101). Logistic regression analysis determined odds ratios for developing AEs. In tenofovir-containing regimens decreased ITPase activity was associated with less AEs (p = 0.01) and longer regimen duration (p = 0.001). In contrast, in abacavir-containing regimens decreased ITPase activity was associated with more AEs (crude p = 0.02) and increased switching of medication due to AEs (p = 0.03). ITPA genotype wt/wt was significantly associated with an increase in the occurrence of AEs in tenofovir-containing regimens. Decreased ITPase activity seems to be protective against occurrence of AEs in tenofovir-containing cART, while it is associated with an increase in AEs in abacavir-containing regimens. Public Library of Science 2018-01-12 /pmc/articles/PMC5766130/ /pubmed/29329318 http://dx.doi.org/10.1371/journal.pone.0191069 Text en © 2018 Peltenburg et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Peltenburg, N. Chantal Bierau, Jörgen Bakker, Jaap A. Schippers, Jolanda A. Lowe, Selwyn H. Paulussen, Aimée D. C. van den Bosch, Bianca J. C. Leers, Mathie P. G. Hansen, Bettina E. Verbon, Annelies Erythrocyte Inosine triphosphatase activity: A potential biomarker for adverse events during combination antiretroviral therapy for HIV |
title | Erythrocyte Inosine triphosphatase activity: A potential biomarker for adverse events during combination antiretroviral therapy for HIV |
title_full | Erythrocyte Inosine triphosphatase activity: A potential biomarker for adverse events during combination antiretroviral therapy for HIV |
title_fullStr | Erythrocyte Inosine triphosphatase activity: A potential biomarker for adverse events during combination antiretroviral therapy for HIV |
title_full_unstemmed | Erythrocyte Inosine triphosphatase activity: A potential biomarker for adverse events during combination antiretroviral therapy for HIV |
title_short | Erythrocyte Inosine triphosphatase activity: A potential biomarker for adverse events during combination antiretroviral therapy for HIV |
title_sort | erythrocyte inosine triphosphatase activity: a potential biomarker for adverse events during combination antiretroviral therapy for hiv |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766130/ https://www.ncbi.nlm.nih.gov/pubmed/29329318 http://dx.doi.org/10.1371/journal.pone.0191069 |
work_keys_str_mv | AT peltenburgnchantal erythrocyteinosinetriphosphataseactivityapotentialbiomarkerforadverseeventsduringcombinationantiretroviraltherapyforhiv AT bieraujorgen erythrocyteinosinetriphosphataseactivityapotentialbiomarkerforadverseeventsduringcombinationantiretroviraltherapyforhiv AT bakkerjaapa erythrocyteinosinetriphosphataseactivityapotentialbiomarkerforadverseeventsduringcombinationantiretroviraltherapyforhiv AT schippersjolandaa erythrocyteinosinetriphosphataseactivityapotentialbiomarkerforadverseeventsduringcombinationantiretroviraltherapyforhiv AT loweselwynh erythrocyteinosinetriphosphataseactivityapotentialbiomarkerforadverseeventsduringcombinationantiretroviraltherapyforhiv AT paulussenaimeedc erythrocyteinosinetriphosphataseactivityapotentialbiomarkerforadverseeventsduringcombinationantiretroviraltherapyforhiv AT vandenboschbiancajc erythrocyteinosinetriphosphataseactivityapotentialbiomarkerforadverseeventsduringcombinationantiretroviraltherapyforhiv AT leersmathiepg erythrocyteinosinetriphosphataseactivityapotentialbiomarkerforadverseeventsduringcombinationantiretroviraltherapyforhiv AT hansenbettinae erythrocyteinosinetriphosphataseactivityapotentialbiomarkerforadverseeventsduringcombinationantiretroviraltherapyforhiv AT verbonannelies erythrocyteinosinetriphosphataseactivityapotentialbiomarkerforadverseeventsduringcombinationantiretroviraltherapyforhiv |